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Abstract: Salmonella enterica subspecies enterica serovar Typhi is the aetiological agent of typhoid or
enteric fever. In a subset of individuals, S. Typhi colonizes the gallbladder causing an asymptomatic
chronic infection. Nonetheless, these asymptomatic carriers provide a reservoir for further spreading
of the disease. Epidemiological studies performed in regions where S. Typhi is endemic, revealed that
the majority of chronically infected carriers also harbour gallstones, which in turn, have been indicated
as a primary predisposing factor for the onset of gallbladder cancer (GC). It is now well recognised,
that S. Typhi produces a typhoid toxin with a carcinogenic potential, that induces DNA damage and
cell cycle alterations in intoxicated cells. In addition, biofilm production by S. Typhi may represent a
key factor for the promotion of a persistent infection in the gallbladder, thus sustaining a chronic local
inflammatory response and exposing the epithelium to repeated damage caused by carcinogenic
toxins. This review aims to highlight the putative connection between the chronic colonization by
highly pathogenic strains of S. Typhi capable of combining biofilm and toxin production and the
onset of GC. Considering the high risk of GC associated with the asymptomatic carrier status, the
rapid identification and profiling of biofilm production by S. Typhi strains would be key for effective
therapeutic management and cancer prevention.
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1. Epidemiology and Risk Factors
Salmonella enterica subspecies enterica serovar Typhi is a rod shaped, flagellated, aerobic,
Gram-negative bacterium. It is a human-specific pathogen that causes typhoid or enteric fever [1].
The most frequent cause of infection by S. Typhi is the consumption of contaminated food or water.
After ingestion, S. Typhi establishes a systemic infection by invading the mucosal surface of the
intestine, spreading into the liver, spleen, pancreas and bone marrow [2]. The multi-systemic
complications associated with S. Typhi infection can lead to a fatal outcome if diagnosed late or
not effectively treated.
The major symptom of the disease is a non-specific fever [2], which increases during the first
week of the illness, generally reaching a steady phase in the second week with temperatures around
39–40 ◦C, with few diurnal variations.
Other common symptoms include chills, headache, malaise, anorexia, a dry cough, sore
throat, and myalgia, thus resembling more common seasonal viral infections. The presence of
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skin manifestations is not unusual, characterized by the presence of a non-itching erythematous
maculopapular rash [3–5], generally located on the chest, abdomen and occasionally on the back, arms,
legs and genitals [1,6].
S. Typhi causes 22 million cases of typhoid fever, 5.4 million cases of paratyphoid fever and
216,000 deaths worldwide annually [7,8]. In regions where S. Typhi is endemic approximately 1–4%
of infected individuals become chronic asymptomatic carriers representing a threat to local public
health [9,10]. Chronic infection with S. Typhi, which is generally localized in the gallbladder, is
classically associated with long-term excretion of bacteria [11]. Although carriers have frequent biliary
tract disease, this condition is not thought to be necessary for development of the carrier status [12–14].
Epidemiological studies performed in S. Typhi endemic regions, such as Chile, Bolivia, Ecuador,
as well as some areas of India, Pakistan, Japan and Korea, have shown that approximately 90% of
chronically infected carriers are also gallstones carriers, and this association is, in turn, indicated as a
major predisposing factor for the development of gallbladder cancer (GC) [15–19].
GC is the sixth most common gastrointestinal tract cancer and represents one of the most
widespread biliary tract malignancies [20]. The worldwide annual incidence of GC is approximately
2/100,000 individuals, with marked ethnic and geographical variations [21]. The highest incidence
rates were found among South Americans, in American–Indians, in the north of India, in Pakistan
and Korea. In several European and North American countries, GC is rare and mortality is declining,
although relatively high incidence and mortality rates are still reported in some central European
countries [20]. The malignancy has been associated with genetics and life style, but S. Typhi infection
and gallstone disease represent the most important risk factors [22]. Gallstone size increases the risk of
GC. When stones exceed 3 cm the risk is tenfold higher compared with smaller stones [23,24].
The survival rate, after five years is reported to be around 30% for lesions confined to the
gallbladder mucosa but this percentage drops to 10% after one year for more advanced stages of the
disease [25]. Although the interplay of multiple factors is likely to contribute to the development of
the malignancy, the association with a chronic S. Typhi infection has been observed and repeatedly
confirmed since 1971 [26].
Strong epidemiological evidence of the association between S. Typhi infection and GC came from
retrospective studies conducted in the United States and in Europe, proving that chronic S. Typhi
carriers were exposed to a significantly higher risk of death from GC in comparison with otherwise
healthy individuals [27]. Typhoid and paratyphoid carriers, enrolled in the study during the typhoid
outbreak of 1994 in Scotland, showed a greater probability of GC, and to a lesser extent, pancreas,
colo-rectum and lung cancer as well as other less frequent neoplasms [15]. Subsequent studies
confirmed these observations, linking typhoid carriers with an increased incidence of cancer of the
hepatobiliary system, although lacking any serological evidence [28]. Conversely, serological studies
conducted in northern India, showed that the rates of S. Typhi isolation from bile, gallbladder tissue
and gallstones from patients with GC were significantly higher as compared to those of patients
suffering from benign gallbladder diseases [16,29,30]. The frequencies of individuals having clinically
significant anti-Vi serum antibody titres were 38.5% for GC patients, 13.9% for patients with benign
gallbladder diseases, and 9.2% for healthy individuals. More recently, a specific nested PCR technique,
developed to overcome the limitations of serology test and culture isolation, revealed the presence
of the S. Typhi flagellin gene in 67.3% of hepatobiliary samples collected from GC patients while in
patients with benign gallbladder diseases and healthy population this percentage was significantly
reduced [17,31].
The hypothesis of a causative link between S. Typhi and GC has been reinforced by several
studies performed in Chile that present incidence rates of GC of 12.8/100,000 cases in women and
6.3/100,000 in men, which are among the highest in the world [27]. This study, which involved culture
assessment and quantitative PCR, showed a positive correlation between S. Typhi and GC, suggesting
that the early detection of S. Typhi is critical in order to develop prevention strategies for gallbladder
carcinogenesis [27].
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Histologically, over 90% of gallbladder cancers are adenocarcinoma and more than 80% of
cases are also associated with the presence of gallstones [25,32]. Indeed, strong epidemiological
evidence correlates the presence of GC with the chronic S. Typhi carrier status in association with
gallstones [19,33].
Although a positive correlation between S. Typhi and GC is well documented, the mechanism(s)
for its chronic persistence as well as the putative carcinogenic mechanisms promoted by S. Typhi
are still debated. The production of biofilm may exert a key role in supporting the colonization and
chronic persistence of S. Typhi. This notion is supported by several reports documenting that the
bile, a lipid-rich, detergent-like digestive secretion with antimicrobial properties contained in the
gallbladder, induces the production of an exopolysaccharide matrix O-antigen that facilitates S. Typhi
biofilm formation on human gallstones [34,35]. Thus, biofilm embedded gallstones may represent a
most favourable environment for bacterial persistence in the gallbladder and may lead to reseeding
of the intestine and faecal shedding, with the ensuing transmission to a new host, while chronically
exposing the gallbladder epithelium to bacterial factors with potential carcinogenic properties.
2. Potential Carcinogenic Activity of S. Typhi
Different products released by S. Typhi have the potential to promote carcinogenesis
including bacterial glucuronidase and nitroso compounds [25]. In addition, S. Typhi also
produces a toxic molecule, belonging to the group of the cytolethal distending toxins (CDT),
which induces DNA damage and triggers an irreversible cell cycle arrest and apoptosis [36].
The presence of CDT has been identified in several Gram-negative bacterial species including: E. coli,
Campylobacter spp., Shigella dysenteriae, Actinobacillus actinomycetemcomitans, Haemophilus ducreyi and
numerous enterohepatic Helicobacter spp. [37]. CDTs are normally encoded by three different genes,
cdtA, cdtB, and cdtC, organized as an operon encoding three polypeptides (CdtA, CdtB, and CdtC), which
are assembled as a heterotrimeric toxin [37–39]. This molecule has an active unit called CdtB which
possesses structural and functional homology with the mammalian DNAse-I [40,41]. Several studies
reported that CdtB causes double stranded breaks in host cell chromosomal DNA, activating the DNA
damage response (DDR) [36,42,43].
CDT toxic activity was first identified from clinical isolates of Escherichia coli [44]. In vitro
experiments demonstrated that this toxin triggers cell cycle arrest and ultimately cell death in some
cultured mammalian cells [45]. In the tripartite toxin complex, the CdtB is the active subunit that
functions as a DNAse I, while CdtA and CdtC mediate the binding of the holotoxin to the plasma
membrane of the target cells. Once CdtB penetrates into the target cells it induces limited double
strands breaks (DSB), leading to activation of the ataxia-teleangiectasia mutated (ATM)-dependent
DNA damage responses and the formation of DNA repair complexes [42,46]. S. Typhi represents
an exception to the conventional CdtA–CdtB–CdtC tripartite structure characteristic of the CDT
family [40,47]. It possesses an open reading frame (ORF) encoding a protein with a high amino acid
sequence similarity to CdtB but does not present an ORF with amino acid sequence similarity to
CdtA or CdtC [40]. Hence, CdtB is not associated with CdtA and CdtC, but its activity relies on the
expression of two genes, resembling the B components of pertussis toxin, named pertussis-like toxin A
(pltA) and pertussis-like toxin B (pltB). The structure of typhoid toxin revealed an A2B5 organization
with the CdtB and PltA covalently linked in the A subunit and associated with the PltB homopentamer
forming the B subunit. The C-terminal region of PltA forms an alpha-helix inserted into the channel
formed by the PltB pentamer maintained by hydrophobic interactions [48].
The primary target for typhoid toxin binding are glycoproteins, mediated by the PltB
pentamer [48,49]. Typhoid toxin binds to different glycans, exhibiting a specific preference for
those with terminal sialic acids. Human sialoglycans differ from those present in other mammals,
representing a central factor in the S. Typhi’s host specificity [49].
The S. Typhi CdtB–PltA–PltB tripartite complex, after being delivered to the target cell, reaches the
nucleus of the target cell inducing DNA damage [36,40,50]. The mechanism of action of the tripartite
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complex reflects the specific mode of infection of S. Typhi. Expression of cdtB, pltA, and pltB take
place only after bacterial internalization into host cells [36,40]. When S. Typhi reaches an intracellular
compartment, it releases the CdtB–PltA–PltB complex into the vacuole [36,40]. The complex is then
transported to the plasma membrane and secreted to the extracellular medium from where it can target
neighbouring non-infected cells inducing DNA damage and G2 cell cycle arrest [36,40,41,48]. Entry of
the typhoid toxin into target cell occurs via endocytosis (Figure 1). The PltB and PltA subunits are
probably required to transport CdtB from the site of production within the cells to the external cellular
compartment [51]. This finding originated from the observation that during bacterial infection of
tissue culture cells, the CdtB toxin can exert its effects on both infected and non-infected cells, inducing
cell cycle arrest and cellular distension [40]. Comparative studies, based on CDTs produced by other
bacterial species, suggest that the typhoid toxin may follow an endocytic trafficking similar to that
described for other AB-type toxins. This would result in typhoid toxin internalization by endocytosis,
transport to the Golgi complex and then to the endoplasmic reticulum (ER) [41,52–56]. Subsequently,
the activated CdtB subunit translocates to the host cell nucleus inducing DNA damage [53]. The activity
of CdtB originates from toxin-mediated DNA damage, which activates the cellular DNA damage
response. Indeed, CdtB possesses catalytic residues with eukaryotic DNase I, activities, suggesting that
this protein might function as an intracellular-acting DNase [42,57–60]. In vitro studies also indicated
that CdtB acts as a nuclease cleaving DNA substrate, inducing nuclear fragmentation and chromatin
disruption either in mammalian cells or in Saccharomyces cerevisiae, and promoting DNA fragmentation
in cells exposed to the purified soluble toxin [42,57,61,62]. The DNA damaging activity of the CdtB
toxin activates a cascade of events (Figure 2) which include the classical DNA damage response,
with the recruitment of the DNA damage sensor complex Mre11-Rad50-Nbs1 (MRN), which initiates
DNA end resection to produce a 3′ tail with the accumulation and full activation of the ATM kinase
at the site of the damage [63]. As a consequence, activation of ATM promotes phosphorylation of
histone H2AX, a member of the histone 2A family and activation of several DNA damage checkpoints
including the tumour suppressor p53 and its downstream effector p21, which induces cell cycle arrest
in G1 [64]. Additionally, ATM activates the checkpoint kinases 2 (CHK2), that causes inactivation of the
cell division cycle 25 (CDC25) phosphatase. CHK2-dependent inactivation of the CDC25 leads to an
accumulation of the hyperphosphorylated form of the cyclin-dependent checkpoint kinases 1 (CDK1)
that, in turn, blocks cell proliferation in the G2/M phase [46,65–68]. In some cases, CdtB-exposed
normal or tumour cells showed 53BP1⁄cH2AX-positive foci, senescence associated b-galactosidase
activity, and expansion of promyelocytic nuclear compartments that represent hallmarks of transition
into cellular senescence [69]. Thus, the carcinogenic potential of the genotoxins released by S. Typhi
can also be indirectly linked to the activation of survival signalling pathways that induces cells with
DNA damage to acquire genomic instability and mutations by activating the DNA damage checkpoint
responses. In fact, the survival of cells accumulating DNA damage and with genomic instability is
considered to be a major cause of cancer [70].
The survival of cells exposed to CDT relies on the activation of the small GTPase Ras homolog
gene family, member A (RhoA), which promotes the formation of actin stress fibres [62]. This process
is not directly caused by the toxin, but is the consequence of the ATM-induced cellular responses to
genotoxic stresses. Activation of RhoA, mediated by the ATM kinase, prevents cell death via activation
of p38 and its downstream target mitogen-activated protein kinase-activated activated protein kinase
2 (MK2) prolonging cell survival [71]. Indeed, factors that disrupt cell cycle progression may induce
the acquisition of mutations. This might be achieved by a mechanism analogous to genotoxic agents
such as Reactive Oxigen Species (ROS) and Reactive Nitrogen Species (RNS), that increase the rate
of mutations within the genome [72,73]. Therefore, CdtB-induced activation of survival responses
in cells harbouring DNA damage could contribute to the accumulation of genetic instability within
the developing inflammatory microenvironment, providing the ideal background for promoting the
transformation of pre-neoplastic cells to malignant cells in the host. To what extent the activation of the
DDR by the typhoid toxin provides an evolutionary advantage to S. Typhi is unclear. S. Typhi is strictly
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a human pathogen and evaluation of the direct effect of the typhoid toxin in vivo is a challenging
task. In a recent publication, immunocompetent mice, with an unperturbed microbiota, were orally
infected with isogenic S. enterica, serovar Typhimurium strains, producing either a functional or an
inactive typhoid toxin. In this model, the typhoid toxin was detected ten days post-infection in the
liver of infected mice. Surprisingly, it was found that typhoid toxin favored the survival of the host,
promoting a significant reduction of severe enteritis in the early phases of infection. Subsequent
analysis confirmed that the functional typhoid toxin suppressed the intestinal inflammatory response
and increased the frequency of asymptomatic carriers [74,75]. Induction of DNA damage and activation
of ATM by oxidative burst, suppress cytokine production in purified human neutrophils activated by
bacterial elements (LPS flagellin and zymogen) [76]. From an evolutionary prospective, the activation
of the DDR by the typhoid toxin may suppress the inflammatory response in support of a chronic
infection. In this scenario, carcinogenesis could represent collateral damage of the prolonged release
of the typhoid toxin. In addition to the typhoid toxin, recent studies showed the ability of S. enterica
to induce cellular transformation through the activation of host pathways capable of promoting
bacterial uptake and its intracellular survival [77]. This mechanism is mediated by the activation of
the host Mitogen-activated protein kinase (MAPK) and by the AKT pathway, which regulate cellular
proliferation, growth, and apoptosis [77,78]. Invasion of epithelial cells by S. enterica is promoted
by type III secretion system (T3SS-1) encoded by S. enterica pathogenicity island 1 (SPI1) and the
T3SS-1 secreted bacterial effectors SopB, SopE, SopE2, SptP and SipA required for invasion and
entry into cells [79]. Bacterial effectors activate MAPK and AKT pathways which in turn induce
the transformation of cells harboring inactivated p53 and overexpressing the MYC oncogene [77],
as observed in tissue samples of GC tumors isolated from Indian patients infected by S. Typhi [77,80].
Figure 1. Proposed model for the intracellular trafficking of the typhoid toxin. (A) The PltB subunits
bind to the host cell surface receptor; (B) Endocytosis of the typhoid toxin; (C) Endosome-mediated
delivery of the typhoid toxin to the Golgi complex; (D) Passage of the typhoid toxin through the Golgi
complex; (E) Entry of the typhoid toxin into the endoplasmic reticulum (ER) and release of the CdtB
component from the holotoxin (F) Entry of the CdtB subunit into the nucleus and induction of DNA
damage [46–48].
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Figure 2. CdtB induced double strand breaks and activation of the ataxia-teleangiectasia mutated
(ATM) signalling network. ATM is recruited and fully activated to the site of double-strand break (DSB)
by the Mre11-Rad50-Nbs1 (MRN) complex. Adjacent to the site of damage, ATM phosphorylates the
histone H2AX (γH2AX) which in turn promotes chromatin remodeling and ATM retention at the site of
damage. ATM phosphorylates and activates the downstream effector checkpoint kinases 1 (CHK1) and
2 (CHK2). CHK1 activation induces the accumulation and stabilization of p53 which transcriptionally
activates the target gene p21. CHK2 phosphorylates and inhibits the cell division cycle 25 (CDC25),
leading to the downstream hyperphosphorylation and inactivation of the cyclin dependent cell division
cycle 2 (CDC2) kinase. The checkpoints modulation, mediated by ATM, induces cell cycle arrest either
in the G1 or G2 phases of the cell cycle to allow the DNA damage repair, alternatively, when the damage
cannot be repaired, this response drives the cell to apoptosis or cellular senescence. The ATM signaling
in the cytosol activates the Ras homolog gene family, member A (RhoA). This process results in the
activation of the RhoA/Rho-associated, coiled-coil containing protein kinase 1 (ROCK) axis which
modulates the organization of the actin cytoskeleton, and in the activation of the p38-mediated cell
survival pathway.
3. Biofilm-Mediated S. Typhi Persistence in the Gallbladder
The establishment of S. Typhi chronic carrier status is associated in 80–90% of cases with the
presence of cholesterol gallstones [81]. On the other hand, the simultaneous presence of S. Typhi
and gallstones is associated with increased risk for the development of GC [16,82,83]. The use of
high-dose, prolonged antibiotic treatment is not always capable of eradicating S. Typhi colonization
of the gallbladder in chronically infected patients, although partial efficacy has been observed in
patients without gallstones [12,82]. Although cholecystectomy has been proved to increase the rate
of resolution, additional sites of infection have been observed in the liver, biliary tree and mesenteric
lymph nodes [18,25]. The chronic persistence, the difficulty in the therapeutic eradication of S. Typhi
colonization together with its ability to evade the host immune response in carriers, strongly suggests
the presence of a typical biofilm-related microbial disease [18]. Indeed, previous reports have shown
the presence of biofilm-coated gallstones in asymptomatic human carriers, in mouse models and on the
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gallbladder epithelium of mouse carriers, providing direct evidence that biofilm production by S. Typhi
may play a pivotal role for the establishment of a chronic colonization in the gallbladder [18,33,84,85].
Gallbladder tissues from patients undergoing cholecystectomy showed the presence of S. Typhi
colonization and the microscopic observation of gallstones revealed a consistent biofilm formation
on their surface [86,87]. Enterobacteriaceae, different from S. Typhi, have frequently been recovered
from gallbladder tissues and gallstones [88,89]. In the latter, however, gallstones are not massively
covered by bacterial biofilm as in the case of S. Typhi, suggesting that S. Typhi may have adopted a
specific strategy, which relies on biofilm production on the gallstone’s surface, to chronically persist in
the gallbladder and support the continuous microbial shedding and reattachment process, followed by
bacterial diffusion via urine and faeces, as observed in chronic carriers [33,84,90].
This notion is reinforced by in vivo studies performed in a mouse model fed with a lithogenic
diet (1% cholesterol and 0.5% cholic acid), to promote the development of cholesterol gallstones.
The results showed an enhanced colonization of the gallbladder as compared to infected mice lacking
gallstones [33]. Additionally, the infected mice with gallstones had an increased level of faecal shedding
of S. Typhimurium, as compared with infected mice lacking gallstones. The subsequent microscopic
analysis of the gallstones showed the presence of a dense bacterial biofilm covering the surface [33].
Colonization of the gallbladder exposes S. Typhi to bile, a complex digestive secretion containing
bile acids, cholesterol, phospholipids and bilirubin, that possesses strong antimicrobial properties [91].
S. Typhi tolerates this apparently hostile environment indicating that bile resistance is a central
pathogenetic process in both acute and chronic gallbladder infection [34]. Furthermore, bile can
also induce pleiotropic responses in Salmonella spp, as well as in other enteric pathogens, such
as Campylobacter jejuni [92], Escherichia coli [93], Listeria monocytogenes [94] and Vibrio cholerae [95],
regulating the expression of numerous genes [18]. Interestingly, it has been previously demonstrated
that S. Typhi forms biofilm on human gallstones and cholesterol-coated Eppendorf tubes in a process
mediated by the presence of bile [34,90]. Indeed, bile exerts a profound effect on direct or indirect
gene regulation in S. Typhi [34,96,97] by downregulating the expression of genes involved in host
cell invasion and motility and outer membrane proteins [34,84,98,99]. Indeed, the notion that
biofilm-producing S. Typhi can successfully adapt to the gallbladder environment is further reinforced
by clinical evidence showing that S. Typhi isolates from gallbladder carriers exhibit a common genetic
profile, distinct from strains infecting other organ sites [100], with specific phenotypic traits including
an increased biofilm forming ability [19,87]. On the other hand, it has been shown that Salmonella
colonization can be compromised by infiltrating cells that do not produce biofilm together with biofilm
producing bacteria. In fact, the infiltration with biofilm non-producer cells gave rise to a delayed and
milder disease development in the murine model, which was accompanied by a higher susceptibility
to antibacterial agents [101]. Thus, biofilm formation appears to be a key adaptive strategy adopted by
S. Typhi in order to allow microbial persistence, sustaining an increased resistance against antibiotics
and the host immune response while ensuring microbial spreading in the host and the community.
Chronic persistence represents a key element for prolonging the mutagenic effect of bacterial toxins on
target cells, which may lead to cumulative damages and transformation.
4. Conclusions
Gallbladder colonization and chronic persistence of S. Typhi appears to be favoured by biofilm
formation, which is most effective on the surface of the gallstone. Several studies have described the
strong association between the development of a chronic carrier status and the presence of gallstones.
On the other hand, biofilm formation on gallstones has also been consistently observed and bile and
cholesterol have been found to enhance bacterial adhesion [18,84]. Nevertheless, chronic S. Typhi
infection is still considered as the primary predisposing factor for the development of GC in individuals
with specific predisposing factors, independently from the presence of gallstones. Although, in vivo
and in vitro evidence has demonstrated that S. Typhi can form biofilm on gallstones and that the
presence of biofilm on gallstones is a hallmark of typhoid carriage, the putative link between the
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prevalence of GC and biofilm coated gallstones has been not adequately explored so far. In addition to
gallstones, other sites, such as the gallbladder epithelium, should be considered as alternative niches
for S. Typhi chronic infection [18]. Additional studies will be required to investigate the possible
association between biofilm-producing S. Typhi, chronic carriers with gallstones and the onset of GC.
Characterization of the molecular mechanisms involved in biofilm formation on gallstones and the
activity exerted by S. Typhi in promoting gallbladder inflammation and damage also remain to be
further investigated. The chronic production of genotoxins and free radicals with immunomodulatory
properties may further induce DNA damage and mutations in gallbladder tissue. The presence of the
CDT complex, which induces DNA damage as well as the activation of MAPK and AKT pathways,
indicates that S. Typhi can promote cell transformation and GC particularly in genetically predisposed
individuals. Thus, S. Typhi may be responsible for stable transformative effects in the host cells through
a multi-step process involving colonization, chronic persistence and toxin production (Figure 3).
Figure 3. Possible role of biofilm-producing S. Typhi in gallbladder cancer development. (A) Chronic
infection with S. Typhi strains and the presence of gallstones strongly correlates with gallbladder
cancer (GC) development; The presence of gallstones (B) may provide the ideal substrate for S. Typhi
strains with an increased biofilm forming ability; (C) Once the biofilm is established bacterial cells
can detach from the gallstones releasing carcinogenic molecules that induce genomic instability and
chronic inflammation which represent key prerequisites for the onset of GC.
It has been proposed that bacterial degradation of bile salts and other bacterial byproducts could
cause GC [83]. This mechanism resembles that recently proposed for intestinal bacteria with the
potential to induce colon cancer (CC) by the release of polyamine metabolites. Interestingly, in this
process biofilm plays a central role by upregulating polyamine metabolites that affect the growth
of cancer cells, and creating favorable conditions for oncogenic transformation in colonic epithelial
cells. [102,103]
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Additional studies should aim at evaluating strategies for the prevention of biofilm formation on
the gallstone surface. New clinical laboratory tests to assess biofilm formation as well as to determine
the antibiotic resistance profiles of biofilm-forming bacteria should be introduced. The identification of
high-risk infections, such as those sustained by strong biofilm producing S. Typhi, may support the
most effective therapeutic interventions for microbial eradication [104]. Antibiotic treatment selected
on the basis of the conventional antimicrobial susceptibility testing are frequently ineffective in the
eradication of bacteria associated in biofilm [105]. Once the biofilm is established, the individual
cells exhibit an increased tolerance to antimicrobial agents and the antibiotic treatment alone is often
inadequate. Within a biofilm matrix, microbial cells show 10–1000 times higher minimal inhibitory
concentration (MIC) than the same bacterial cells examined in planktonic growth conditions [106,107].
The effective antibiotic MIC in vivo for biofilm eradication may be impossible to achieve by the
administration of antibiotics at doses that appear effective in planktonic growth, due to the toxicity
and the side effects of the drugs.
Our preliminary results, aimed at evaluating the level of biofilm production by the clinical
Biofilm Ring Test (cBRT), revealed that biofilm is a major virulence determinant in chronic skin ulcers
and it is critical in the failure of the antibiotic treatment in patients with medical devices-related
infections [108–110]. The timely recognition of a high biofilm producer, before the development of a
mature biofilm matrix, may help direct a more appropriate targeting of the therapeutic intervention
(type, doses, duration) and decision-making (e.g. catheter removal). In the case of S. Typhi the rapid
identification of strong biofilm-producing strains may identify high risk patients, thus supporting
clinicians in the prevention of microbial-associated cancers.
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